Multicolor fluorescence in situ hybridization (M-FISH) on cells from urine for the detection of bladder cancer

Junker, Kerstin; Fritsch, T.; Hartmann, Arndt; Schulze, Wolfgang; Schubert, Jöerg

doi:10.1159/000094214

Cited by 35 publications

(22 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After removal of reviews, meta-analyses, and redundant trials, 21 studies assessable for criteria concerning assay performance and comprising 2,852 individuals were identified, forming the basis for this assessment of assay performance [18,34,35,36,84,86,87,88,89,90,91,95,118,119,120,121,122,123,124,125,126,127]. …”

Section: Cell-based Assaysmentioning

confidence: 99%

Molecular Markers for Bladder Cancer Screening, Early Diagnosis, and Surveillance: The WHO/ICUD Consensus

et al. 2014

View full text Add to dashboard Cite

Due to the lack of disease-specific symptoms, diagnosis and follow-up of bladder cancer has remained a challenge to the urologic community. Cystoscopy, commonly accepted as a gold standard for the detection of bladder cancer, is invasive and relatively expensive, while urine cytology is of limited value specifically in low-grade disease. Over the last decades, numerous molecular assays for the diagnosis of urothelial cancer have been developed and investigated with regard to their clinical use. However, although all of these assays have been shown to have superior sensitivity as compared to urine cytology, none of them has been included in clinical guidelines. The key reason for this situation is that none of the assays has been included into clinical decision-making so far. We reviewed the current status and performance of modern molecular urine tests following systematic analysis of the value and limitations of commercially available assays. Despite considerable advances in recent years, the authors feel that at this stage the added value of molecular markers for the diagnosis of urothelial tumors has not yet been identified. Current data suggest that some of these markers may have the potential to play a role in screening and surveillance of bladder cancer. Well-designed protocols and prospective, controlled trials will be needed to provide the basis to determine whether integration of molecular markers into clinical decision-making will be of value in the future.

show abstract

Section: Cell-based Assaysmentioning

confidence: 99%

Molecular Markers for Bladder Cancer Screening, Early Diagnosis, and Surveillance: The WHO/ICUD Consensus

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The loss of the 9p21 locus, site of the p16 tumour suppressor gene, is the earliest and most frequent genetic aberration in bladder cancer. 62 Recent published series on the FISH assay have demonstrated results in the range of 68.6%-100% and 65.0%-96.0% for sensitivity and specificity, respectively 18,28,30,35,39,43,44,58,62,63 (Table 1). Thus the UroVysion assay, which has received FDA approval for the detection of recurrent bladder cancer, is more sensitive than urinary cytology but provides a similar, or slightly lower, specificity.…”

Section: Urovysionmentioning

confidence: 99%

Biomarkers for detection and surveillance of bladder cancer

Budman

Kassouf

Steinberg

2013

CUAJ

126

View full text Add to dashboard Cite

Introduction: Bladder cancer is the fourth most common cancer in men and the ninth most common cancer in women in Canada. Early detection of tumours is essential for improved prognosis and long-term survival. The standard method for detection and surveillance is cystoscopy together with urine cytology. Cystoscopy is relatively sensitive but is expensive and invasive. Urinary cytology is a noninvasive method that has poor sensitivity but high specificity; it is relied on for the detection of carcinoma in situ. Currently, several urinary based bladder tumour biomarkers with USFDA/Health Canada approval are available commercially, but none have been widely adopted by urologists despite their offering high sensitivity and/or specificity. We present here a review of recent studies evaluating 7 commercial biomarker assays for the detection and/or surveillance of bladder cancer.Results: Sensitivity and specificity ranges, respectively, for each marker were reported as follows: BTA Stat (Polymedco), 52.5%–78.0% and 69.0%–87.1%; BTA Trak (Polymedco), 51%–100% and 73%–92.5%; cytology, 12.1%–84.6% and 78.0%–100%; hematuria dipstick, 47.0%–92.6% and 51.0%–84.0%; NMP22 Bladder Cancer Test (Matritech), 34.6%–100% and 60.0%–95.0%; NMP22 BladderChek (Matritech), 49.5%–65.0% and 40.0%–89.8%;ImmunoCyt/uCyt+ (DiagnoCure), 63.3%–84.9% and 62.0%–78.1%; ImmunoCyt/uCyt+ and cytology, 81.0%–89.3% and 61.0%–77.7%; and UroVysion (Abbott Molecular)/florescence in situ hybridization, 68.6%–100% and 65.0%–96.0%.Conclusion: We find that no currently available bladder cancer urinary marker is sensitive enough to eliminate the need for cystoscopy. In addition, cytology remains integral to the detection of occult cancer. However, owing to their relatively high sensitivities, these markers may be used to extend the period between cystoscopies in the surveillance of patients with transitional cell carcinoma. Further study is required to determine which markers, alone or in panel, would best accomplish this.

show abstract

“…Voided cells can be easily obtained and isolated from urine and analysed by a multi-target FISH technique using hybridisation probes to chromosomes 3, 7, 9p21 and 17. The multi-target FISH has a well recognised and important role in the management of bladder cancer 1 46 – 49. This technique is now standardised and is easily applicable to routine material.…”

Section: Non-gynaecological Exfoliative Cytologymentioning

confidence: 99%

Molecular techniques in cytopathology practice

et al. 2007

View full text Add to dashboard Cite

In the last decade, new molecular techniques were introduced into pathology laboratories. Cytology also benefited from the innovations emerging from this new era. Molecular cytopathology (MCP) can be defined as molecular studies applied on all types of cytological specimens, namely gynaecology cytology, exfoliative non- gynaecology cytology and fine needle aspirates. The development of many new ancillary techniques has paralleled the emergence of clinical cytology as a major diagnostic specialty. Clinical applications of these techniques have been growing in the last decade. The widespread acceptance of liquid-based systems in gynaecological cytology emphasises the relation between cells and molecules. The increased use of morphology and molecular biology in human papillomavirus-induced lesions for example, showed the potential to optimise, in one single brushed sample, diagnosis and research. Cytology samples from serous effusions, the pulmonary tree, urine, and aspirations, among others, are now likely to be studied by different molecular techniques for diagnosis, prognosis, or even assessment of therapeutic targets. In this review, the main published results concerning the application of molecular techniques in different fields of cytopathology are highlighted, and their applications discussed.

show abstract

Multicolor fluorescence in situ hybridization (M-FISH) on cells from urine for the detection of bladder cancer

Cited by 35 publications

References 33 publications

Molecular Markers for Bladder Cancer Screening, Early Diagnosis, and Surveillance: The WHO/ICUD Consensus

Molecular Markers for Bladder Cancer Screening, Early Diagnosis, and Surveillance: The WHO/ICUD Consensus

Biomarkers for detection and surveillance of bladder cancer

Molecular techniques in cytopathology practice

Contact Info

Product

Resources

About